Review of Industrial Organization

, Volume 1, Issue 4, pp 260–275 | Cite as

Some determinants of entry into the rapeutic drug markets

  • Sillrley S. Yu
Articles

Abstract

This paper investigates empirically some determinants of entry into the U.S. pharmaceutical industry during the period 1964–1974. The statistical findings of the study are consistent with a priori expectations. Market growth is found to provide incentives for entry, Product differentiation, market concentration, and drug innovation are found to be significant barriers to entry into drug markets.

Keywords

Pharmaceutical Industry Product Differentiation Industrial Organization Significant Barrier Statistical Finding 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. (a).
    Adelman, M.A. “Commont on the ‘II‘ Concentration Meosure as a Nuabers-Equivalent,” REVIEW oF ECONOMICS aND STATISTICS, Vol. 51 (February, 1969), pp. 99–101.Google Scholar
  2. (b).
    Baily, Martin N. “Research and Development Cost and Returns: The U.S. Pharmaceutical Industry,” JOURNAL oF POLITICAL ECONOMY, Vol. 80 (January/February, 1972), pp. 70–85Google Scholar
  3. (c).
    Bain, Joe S. BARRIERS tO NEW COMPETITION. Cambridge: Harvard University Press, 1956.Google Scholar
  4. (d).
    Clymer, Harold. “The changing Costs and Risks of Pharmaceutical Innovation,” THE ECONOMICS oF DRUG DEVELOPMENT. J.D. Cooper (ed.). Washington, D.C.: American University Press, 1970.Google Scholar
  5. (e).
    Cosanor, William S. “Research and Competitive Product Differentiation in the Pharmaceutical Industry,” ECONOMICA, Vol. 31 (November, 1964), pp. 372–384.Google Scholar
  6. (f).
    Dewey, Donald. MICROECONOMICS. New York: Oxford University Press, 1975.Google Scholar
  7. (g).
    Duetsch, Larry L. “Structure, Performance, and the Net Rate of Entry into Manufacturing Industries,” SOUTHERN ECONOMIC JOURNAL, Vol. 41 (January, 1975), pp. 450–456.Google Scholar
  8. (h).
    Gort, Michael. “Analysis of Stability and Change in Market Shares,” JOURNAL oF POLITICAL ECONOMY, Vol. 71 (February, 1963), pp. 51–63.Google Scholar
  9. (i).
    Grossack, Irvin M. “Toward an Integration of Static and Dynamic Moasures of Industrinl Concetration,” REVIEW oF ECONOMICS aND STATISTICS, Vol. 47 (August, 1965), pp. 301–308.Google Scholar
  10. (j).
    Ilornbrook, mark C. “Markot Structuro and Advertising in the U.S. Pharmaceutical Industry: Some Implications for Public Policy,” MEDICAL CARE, Vol. 16 (February 1978), pp. 90–109.Google Scholar
  11. (k).
    Jadlow, Joseph M. AN EMPIRICAL STUDY OF THE RELATIONSHIP BETWEEN MARKET STRUCTURE AND INNOVATION IN THERAPEUTIC DRUG MARKETS, 1976. (The final report to the National Science Foundation under Grant No. RDA 75-21075.)Google Scholar
  12. (l).
    McGuckin, Robert. “Entry, Concentration Change, and Stability of Market Shares,” SOUTHERN ECONOMIC JOURNAL, Vol. 38 (January, 1972), pp. 363–370.Google Scholar
  13. (m).
    Mansfield, E., “entry, Gibrat's Law, Innovation and Growth of Firms,” AMERICAN ECONOMIC REVIEW, Vol. 52 (December, 1962), pp. 1023–1050.Google Scholar
  14. (n).
    — “Size of Firm, Market Structure, and Innovation,” JOURNAL oF POLITICAL ECONOMY, Vol. 71 (December, 1963), pp. 556–576.Google Scholar
  15. (o).
    Modigliani, Franco. “New Developments on the Oligopoly Front.” JOURNAL oF POLITICAL ECONOMY, Vol. 66 (June, 1958), pp. 215–232.Google Scholar
  16. (p).
    Mueller, D.C. and Tilton, J.E., “Research and Development Costs as a Barrier to Entry.” CANADIAN JOURNAL oF ECONOMICS, Vol. 2 (November, 1969), pp. 570–579.Google Scholar
  17. (q).
    Needham, Douglas, THE ECONOMICS oF INDUSTRIAL STRUCTURE, CONDUCT, aND PERFORMANCE. New York: St. Martin's Press, 1978.Google Scholar
  18. (r).
    Orr, Dale. “The Determinants of Entry: A study of the Canadian Manufacturing Industries.” REVIEW oF ECONOMICS aND STATISTICS, Vol. 56 (February, 1974), pp. 58–66.Google Scholar
  19. (s).
    Peltzman, S. “An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments.” JOURNAL oF POLITICAL ECONOMY, Vol. 81 (September/October, 1973), pp. 1049–1091.Google Scholar
  20. (t).
    Scherer, F.M. “Firm Size, Market Structure, Opportunity, and the Output of Patened Inventions.” AMERICAN ECONOMIC REVIEW, Vol. 55 (December, 1965), pp. 1097–1125.Google Scholar
  21. (u).
    — INDUSTRIAL MARKET STRUCTURE aND ECONOMIC PERFORMANCE. 2nd edition. Boston: Houghton Mifflin Company, 1979.Google Scholar
  22. (v).
    Schwartzman, David. INNOVATION iN tHE PHARMACEUTICAL INDUSTRY. Baltimore: The Johns Hopkins University Press, 1976.Google Scholar
  23. (w).
    Sylos-Labin, Paolo. OLIGOPOLIO E PROGRESS TECHNICO. Milan: Gluffre, 1957.Google Scholar
  24. (x).
    Telser, Lester G. “The Supply Response to Shifting Demand in the Ethical Pharmaceutical Industry.” DRUG DEVELOPMENT aND MARKETING. Robert B. Helas (ed.). Washington, D.C.: American Enterprise Institute, 1975, pp. 207–223.Google Scholar
  25. (y).
    Telser, Lester G. et al. “The Theory of Supply with Applications to the Ethical Pharmaceutical Industry.” JOURNAL oF LOW aND ECONOMICS, Vol. 18 (October, 1975), pp. 449–478.Google Scholar
  26. (z).
    Wardell, William M. “The History of Drug Discovery, Development and Regulation.” ISSUES iN PHARMACEUTICAL ECONOMICS. Robert I. Chein (ed.) Lexington, Maine: D.C. Health and Company, 1979, pp. 3–11.Google Scholar
  27. (aa).
    Weiss, L.W. “Quantitative Studies of Industrial Organization.” FRONTIERS oF QUANTITATIVE ECONOMICS. M.D. Intriligator (ed.). Amsterdam: North-Holland Publishing Company, 1971, pp. 362–403.Google Scholar
  28. (bb).
    Verson, John M. “Concentration, Promotion, and Market Share Stability in the Pharmaceutical Industry,” JOURNAL oF INDUSTRIAL ECONOMICS, Vol. 19 (July, 1971), pp. 246–266.Google Scholar

Copyright information

© Review of Industrial Organization 1984

Authors and Affiliations

  • Sillrley S. Yu
    • 1
  1. 1.Texas Tech UniversityTexasUSA

Personalised recommendations